Simvastatin
A widely used statin that lowers LDL (bad) cholesterol and triglycerides by reducing the liver's production of cholesterol, helping to prevent heart attacks and strokes. Some research also suggests potential benefits in slowing cognitive decline, though its primary established use remains cardiovascular risk reduction.
Peso Molecular
418,5700 g/mol
LogP
4,70
TPSA
72,80 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Classes de Medicamentos
Mecanismo de Ação
Prodrug converted to active form that inhibits HMG-CoA reductase.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Prodrug converted to active form that inhibits HMG-CoA reductase.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
InChI
InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
Molecular Formula
C25H38O5
HBD / HBA
1 / 5
Ligações Rotacionáveis
7
Átomos Pesados
30
Simvastatin modestly potentiates warfarin anticoagulation, leading to small but potentially clinically relevant INR increases.
Cyclosporine raises simvastatin exposure by 6- to 10-fold through inhibition of CYP3A4, OATP1B1, and P-gp, creating an extremely high risk of rhabdomyolysis.
Amlodipine inhibits CYP3A4-mediated simvastatin metabolism, increasing simvastatin plasma concentrations and the risk of statin-associated myopathy and rhabdomyolysis.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A widely used statin that lowers LDL (bad) cholesterol and triglycerides by reducing the liver's production of cholesterol, helping to prevent heart attacks and strokes. Some research also suggests potential benefits in slowing cognitive decline, though its primary established use remains cardiovascular risk reduction.
Prodrug converted to active form that inhibits HMG-CoA reductase.
Key pharmacokinetic parameters for Simvastatin: Half-life: 2 hours.
Yes, Simvastatin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1064. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54454. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="simvastatin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/simvastatin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/simvastatin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/simvastatin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="simvastatin"></drugfyi-drug>